These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 22027537

  • 1. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
    Jones B, Komarnitsky P, Miller GT, Amedio J, Wallner BP.
    Anticancer Drugs; 2012 Feb; 23(2):173-84. PubMed ID: 22027537
    [Abstract] [Full Text] [Related]

  • 2. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
    Hingorani P, Zhang W, Piperdi S, Pressman L, Lin J, Gorlick R, Kolb EA.
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):733-40. PubMed ID: 19224214
    [Abstract] [Full Text] [Related]

  • 3. Palifosfamide, a bifunctional alkylator for the treatment of sarcomas.
    Jung S, Kasper B.
    IDrugs; 2010 Jan; 13(1):38-48. PubMed ID: 20024846
    [Abstract] [Full Text] [Related]

  • 4. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.
    Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P.
    J Clin Oncol; 2016 Nov 10; 34(32):3898-3905. PubMed ID: 27621408
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of edotecarin in breast carcinoma models.
    Ciomei M, Croci V, Stellari F, Amboldi N, Giavarini R, Pesenti E.
    Cancer Chemother Pharmacol; 2007 Jul 10; 60(2):229-35. PubMed ID: 17089166
    [Abstract] [Full Text] [Related]

  • 6. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.
    Granda TG, Filipski E, D'Attino RM, Vrignaud P, Anjo A, Bissery MC, Lévi F.
    Cancer Res; 2001 Mar 01; 61(5):1996-2001. PubMed ID: 11280758
    [Abstract] [Full Text] [Related]

  • 7. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC.
    Mol Pharmacol; 2008 Mar 01; 73(3):627-38. PubMed ID: 18025070
    [Abstract] [Full Text] [Related]

  • 8. Docetaxel enhances the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner.
    Egawa T, Kubota T, Furukawa T, Otani Y, Watanabe M, Furukawa T, Kumai K, Kitajima M.
    Anticancer Res; 2001 Mar 01; 21(4A):2597-600. PubMed ID: 11724327
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of cryptophycins: effect of infusion time and combination studies.
    Menon K, Alvarez E, Forler P, Phares V, Amsrud T, Shih C, Al-Awar R, Teicher BA.
    Cancer Chemother Pharmacol; 2000 Mar 01; 46(2):142-9. PubMed ID: 10972484
    [Abstract] [Full Text] [Related]

  • 10. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J, Fra J, López-Pousa A, García del Muro X, Balañá C, Casado A, Martín J, Martínez-Trufero J, de las Peñas R, Buesa JM, Spanish Group for Research on Sarcomas (GEIS).
    Cancer; 2004 Apr 01; 100(7):1498-506. PubMed ID: 15042685
    [Abstract] [Full Text] [Related]

  • 11. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M.
    Cancer Chemother Pharmacol; 2008 Sep 01; 62(4):621-9. PubMed ID: 18038274
    [Abstract] [Full Text] [Related]

  • 12. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.
    Clin Cancer Res; 2002 Apr 01; 8(4):1172-81. PubMed ID: 11948130
    [Abstract] [Full Text] [Related]

  • 13. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E, Barichello JM, Ishida T, Kiwada H.
    Int J Pharm; 2008 Apr 02; 353(1-2):65-73. PubMed ID: 18155369
    [Abstract] [Full Text] [Related]

  • 14. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
    Saucier JM, Yu J, Gaikwad A, Coleman RL, Wolf JK, Smith JA.
    J Oncol Pharm Pract; 2007 Mar 02; 13(1):39-45. PubMed ID: 17621566
    [Abstract] [Full Text] [Related]

  • 15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 16. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
    Lee SW, Yun MH, Jeong SW, In CH, Kim JY, Seo MH, Pai CM, Kim SO.
    J Control Release; 2011 Oct 30; 155(2):262-71. PubMed ID: 21704664
    [Abstract] [Full Text] [Related]

  • 17. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV, Wallace RE, Murdock KC, Angier RB, Durr FE, Forbes M.
    Cancer Res; 1982 Feb 30; 42(2):440-4. PubMed ID: 7055799
    [Abstract] [Full Text] [Related]

  • 18. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    J Clin Oncol; 2007 Jul 20; 25(21):3144-50. PubMed ID: 17634494
    [Abstract] [Full Text] [Related]

  • 19. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
    Bissery MC, Vrignaud P, Lavelle F.
    Semin Oncol; 1995 Dec 20; 22(6 Suppl 13):3-16. PubMed ID: 8604451
    [Abstract] [Full Text] [Related]

  • 20. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A.
    Clin Cancer Res; 2009 Jan 01; 15(1):110-8. PubMed ID: 19118038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.